Literature DB >> 18437562

Beta-blocker pharmacogenetics in heart failure.

Jaekyu Shin1, Julie A Johnson.   

Abstract

Beta-blockers (metoprolol, bisoprolol, and carvedilol) are a cornerstone of heart failure (HF) treatment. However, it is well recognized that responses to a beta-blocker are variable among patients with HF. Numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to a beta-blocker, including left ventricular ejection fraction improvement, survival, and hospitalization due to HF exacerbation. This review summarizes the pharmacogenetic data for beta-blockers in patients with HF and discusses the potential implications of beta-blocker pharmacogenetics for HF patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18437562      PMCID： PMC2851851          DOI： 10.1007/s10741-008-9094-x

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  55 in total

Review 1.  Carvedilol.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

2.  A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor.

Authors:  D A Mason; J D Moore; S A Green; S B Liggett
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

3.  Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure.

Authors:  Pascal de Groote; Nicole Helbecque; Nicolas Lamblin; Xavier Hermant; Eugène Mc Fadden; Claude Foucher-Hossein; Philippe Amouyel; Jean Dallongeville; Christophe Bauters
Journal:  Pharmacogenet Genomics       Date:  2005-03       Impact factor: 2.089

4.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.

Authors:  Steven G Terra; Karen K Hamilton; Daniel F Pauly; Craig R Lee; J Herbert Patterson; Kirkwood F Adams; Richard S Schofield; Bernadette S Belgado; James A Hill; Juan M Aranda; Hossein N Yarandi; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

5.  beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

Authors:  Steven G Terra; Daniel F Pauly; Craig R Lee; J Herbert Patterson; Kirkwood F Adams; Richard S Schofield; Bernadette S Belgado; Karen K Hamilton; Juan M Aranda; James A Hill; Hossein N Yarandi; Joseph R Walker; Michael S Phillips; Craig A Gelfand; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2005-03       Impact factor: 6.875

6.  Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Authors:  Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

7.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 8.  Cardiovascular drug class specificity: beta-blockers.

Authors:  Michael J Reiter
Journal:  Prog Cardiovasc Dis       Date:  2004 Jul-Aug       Impact factor: 8.194

9.  Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.

Authors:  J A Johnson; B S Burlew
Journal:  Drug Metab Dispos       Date:  1996-03       Impact factor: 3.922

10.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

Authors:  S A Green; J Turki; M Innis; S B Liggett
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162
View more
  14 in total

Review 1.  Progress toward genetic tailoring of heart failure therapy.

Authors:  John H Lillvis; David E Lanfear
Journal:  Curr Opin Mol Ther       Date:  2010-06

2.  Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling.

Authors:  Robert K Amanfu; Jeffrey J Saucerman
Journal:  Mol Pharmacol       Date:  2014-05-27       Impact factor: 4.436

3.  The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart.

Authors:  Michael Huntgeburth; Karl La Rosée; Henrik ten Freyhaus; Michael Böhm; Petra Schnabel; Martin Hellmich; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

4.  β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.

Authors:  Mohamed H Shahin; Nihal El Rouby; Daniela J Conrado; Daniel Gonzalez; Yan Gong; Maximilian T Lobmeyer; Amber L Beitelshees; Eric Boerwinkle; John G Gums; Arlene Chapman; Stephen T Turner; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Clin Pharmacol       Date:  2019-05-14       Impact factor: 3.126

5.  Practice Variation in Establishing the Adequacy of Beta-Blockers as an Antiarrhythmic Agent in School-Aged Children and Adolescents.

Authors:  Hilal Al Riyami; Arif Hussain; Andrew Warren; Santokh S Dhillon
Journal:  CJC Open       Date:  2020-03-27

Review 6.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

Review 7.  Cardiovascular nursing on human genomics: what do cardiovascular nurses need to know about congestive heart failure?

Authors:  Lorraine Frazier; Shu-Fen Wung; Elizabeth Sparks; Cathy Eastwood
Journal:  Prog Cardiovasc Nurs       Date:  2009-09

Review 8.  Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling.

Authors:  Grazia Daniela Femminella; Vincenzo Barrese; Nicola Ferrara; Giuseppe Rengo
Journal:  Pharmgenomics Pers Med       Date:  2014-09-09

9.  Effect of race on left ventricular ejection fraction decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy: a retrospective analysis.

Authors:  Iosif Kelesidis; Patrick Hourani; Christopher Varughese; Ronald Zolty
Journal:  Drugs R D       Date:  2013-09

10.  Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.

Authors:  Mohamed H Shahin; Daniela J Conrado; Daniel Gonzalez; Yan Gong; Maximilian T Lobmeyer; Amber L Beitelshees; Eric Boerwinkle; John G Gums; Arlene Chapman; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Am Heart Assoc       Date:  2018-02-24       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.